A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
Authors
Meeks, JBellmunt, J
Bochner, B
Clarke, Noel W
Daneshmand, S
Galsky, M
Hahn, N
Lerner, S
Mason, M
Powles, T
Sternberg, C
Sonpavde, G
Affiliation
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.Issue Date
2012-09
Metadata
Show full item recordAbstract
Muscle-invasive bladder cancer (MIBC) is a disease with a pattern of predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved outcomes for MIBC.Citation
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. 2012, 62 (3):523-33 Eur UrolJournal
European UrologyDOI
10.1016/j.eururo.2012.05.048PubMed ID
22677572Type
ArticleLanguage
enISSN
1873-7560ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2012.05.048
Scopus Count
Collections
Related articles
- ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
- Authors: Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012
- Issue date: 2013 Jan
- Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
- Authors: Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G
- Issue date: 2019 Feb
- Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
- Authors: Osanto S, Álvarez Gómez de Segura C
- Issue date: 2020 Dec
- Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
- Authors: Hamid ARAH, Ridwan FR, Parikesit D, Widia F, Mochtar CA, Umbas R
- Issue date: 2020 Oct 14
- PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
- Authors: Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA
- Issue date: 2024 Aug